Advani RH, Buggy JJ, Sharman JP et al (2013) Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol 31:88–94

Article  CAS  PubMed  Google Scholar 

Puente XS, Jares P, Campo E (2018) Chronic lymphocytic leukemia and mantle cell lymphoma: crossroads of genetic and microenvironment interactions. Blood 131(21):2283–2296

Article  CAS  PubMed  Google Scholar 

Chiorazzi N, Rai KR, Ferrarini M (2005) Chronic lymphocytic leukemia. N Engl J Med 352(8):804–815

Article  CAS  PubMed  Google Scholar 

Gribben JG, O’Brien S (2011) Update on therapy of chronic lymphocytic leukemia. J Clin Oncol 29(5):544–550

Article  PubMed  PubMed Central  Google Scholar 

Liu W, Tolar P, Song W, Kim TJ (2020) BCR Signaling and B Cell activation. Immunol,;11

Niemann CU, Wiestner A (2013 December) B-cell receptor signaling as a driver of lymphoma development and evolution. Semin Cancer Biol 23(6):410–421

Singh SP, Dammeijer F, Hendriks RW (2018) Role of Bruton’s tyrosine kinase in B cells and malignancies. Molecular Cancer volume 17, Article number: 57

Alsadhan A, Cheung J, Gulrajani M, Gaglione EM, Nierman P, Hamdy A, Izumi R, Bibikova E, Patel P, Sun C, Covey T, Herman SEM, Wiestner A (2020) Pharmacodynamic analysis of BTK inhibition in patients with chronic lymphocytic leukemia treated with Acalabrutinib. Clin Cancer Res 26(12):2800–2809

Article  CAS  PubMed  PubMed Central  Google Scholar 

O’Brien S, Hillmen P, Coutre S, Barr PM, Fraser G, Tedeschi A, Burger JA, Dilhuydy MS, Hess G, Moreno C, Cramer P, Liu E, Chang S, Vermeulen J, Styles L, Howes A, James DF, Patel K, Graef T, Valentino R (2018) Safety Analysis of Four Randomized Controlled studies of Ibrutinib in patients with chronic lymphocytic Leukemia/Small lymphocytic lymphoma or Mantle Cell Lymphoma. Clin Lymphoma Myeloma Leuk 18(10):648–657

Article  PubMed  Google Scholar 

Chen LS, Bose P, Cruz ND, Jiang Y, Wu Q, Thompson PA, Feng S, Kroll MH, Qiao W, Huang X, Jain N, Wierda WG, Keating MJ, Gandhi V (2018) A pilot study of lower doses of ibrutinib in patients with chronic lymphocytic leukemia. Blood 132(21):2249–2259

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chhina A, Pernia Marin M, Thomas P, Vallejo SG, Cappell E, Jain K (2021) Reduced-dose ibrutinib is well tolerated and cost effective for the Treatment of Chronic Lymphocytic Leukemia in Frail older adults. Blood 138(Supplement 1):4967

Article  Google Scholar 

Akhtar OS, Attwood K, Lund I, Hare R, Hernandez-Ilizaliturri FJ, Torka P (2019) Dose reductions in ibrutinib therapy are not associated with inferior outcomes in patients with chronic lymphocytic leukemia (CLL). Leuk Lymphoma 60(7):1650–1655

Article  CAS  PubMed  Google Scholar 

Marostica E, Sukbuntherng J, Loury D, de Jong J, Woot de Trixhe X, Vermeulen A, De Nicolao, O’Brien S, Byrd JC, Advani R, McGreivy J, Poggesi I (2015) Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies. Cancer Chemother Pharmacol 75(1):111–121

Article  CAS  PubMed  Google Scholar 

EMA European public assessment report: Imbruvica® Publication date: 25/11/2014. https://www.ema.europa.eu/en/documents/assessment-report/imbruvica-epar-public-assessment-report_en.pdf

Saffran DC, Parolini O, Fitch-Hilgenberg ME, Rawlings DJ, Afar DE, Witte ON, Conley ME (1994) Brief report: a point mutation in the SH2 domain of Bruton’s tyrosine kinase in atypical X-linked agammaglobulinemia. N Engl J Med 330(21):1488–1491

Article  CAS  PubMed  Google Scholar 

Hutchinson CV, Dyer MJS (2014) Breaking good: the inexorable rise of BTK inhibitors in the treatment of chronic lymphocytic leukaemia. Br J Haematol 166(1):12–22

Article  CAS  PubMed  Google Scholar 

Evans EK, Tester R, Aslanian S, Karp R, Sheets M, Labenski MT, Witowski SR, Lounsbury H, Chaturvedi P, Mazdiyasni H, Zhu Z, Nacht M, Freed MI, Petter RC, Dubrovskiy A, Singh J, Westlin WF (2013) Inhibition of Btk with CC-292 provides early pharmacodynamic assessment of activity in mice and humans. J Pharmacol Exp Ther 346(2):219–228

Article  CAS  PubMed  Google Scholar 

Lutz JD, Nelson C, Yu H, Liclican A, Feng J, Billin A, Schultz BE, Bresnik M, Mathias A (2016) Pharmacokinetic-pharmacodynamic analysis of GS-4059-Mediated Bruton’s tyrosine kinase inhibition [abstract]. Arthritis Rheumatol; 68 (suppl 10).

Leu JH, Miao X, Shalayda K, Coe KJ, Kahnt A, Wu B, Schnarr M, Franks C, Devlin J, Yang TY, Palmer JA, Zhang M, Zhou H, Van Damme W, Smets S, Aguilar Z, Chaplan SR (2023) A phase 1 first-in-human pharmacokinetic and pharmacodynamic study of JNJ-64264681, a covalent inhibitor of Bruton’s tyrosine kinase. Clin Pharmacol Drug Dev 12(6):611–624

Article  CAS  PubMed  Google Scholar 

Singh J, Petter RC, Baillie TA, Whitty A (2011) The resurgence of covalent drugs. Nat Rev Drug Discov 10(4):307–317

Article  CAS  PubMed  Google Scholar 

Strelow JM (2017) A perspective on the kinetics of Covalent and irreversible inhibition. SLAS Discov 22(1):3–20

Article  CAS  PubMed  Google Scholar 

Khurana P, McWilliams L, Wingfield J, Barratt D, Srinivasan B (2021) A Novel High-Throughput FLIPR Tetra-based method for capturing highly confluent Kinetic Data for structure-kinetic relationship guided early Drug Discovery. SLAS Discov 26(5):684–697

Article  CAS  PubMed  Google Scholar 

Srinivasan B, Flórez Weidinger JD, Zhai X, Lemercier G, Ikeda T, Brewer M, Zhang B, Heyse S, Wingfield J, Steigele S (2022) High-throughput mechanistic screening of non-equilibrium inhibitors by a fully automated data analysis pipeline in early drug-discovery. SLAS Discov 27(8):460–470

Article  CAS  PubMed  Google Scholar 

Burger JA, Buggy JJ (2013) Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765). Leuk Lymphoma 54(11):2385–2391

Article  CAS  PubMed  Google Scholar 

Kaptein A, de Bruin G, Emmelot-van Hoek M, van de Kar B, de Jong A, Gulrajani M, Demont D, Covey T, Mittag D, Barf T (2018) Potency and selectivity of BTK inhibitors in Clinical Development for B-Cell malignancies. Blood 132(Supplement 1):1871

Article  Google Scholar 

R Core Team (2022) R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. https://www.R-project.org/

Baron K (2023) mrgsolve: Simulate from ODE-Based Models. R package version 1.0.8. https://github.com/metrumresearchgroup/mrgsolve

Wickham H, Averick M, Bryan J, Chang W, McGowan LD, François R, Grolemund G, Hayes A, Henry L, Hester J, Kuhn M, Pedersen TL, Miller E, Bache SM, Müller K, Ooms J, Robinson D, Seidel DP, Spinu V, Takahashi K, Vaughan D, Wilke C, Woo K, Yutani H (2019) Welcome to the tidyverse. J Open Source Softw 4(43):1686

Article  Google Scholar 

Krippendorff BF, Neuhaus R, Lienau P, Reichel A, Huisinga W (2009) Mechanism-based inhibition: deriving K(I) and k(inact) directly from time-dependent IC(50) values. J Biomol Screen 14(8):913–923

Article  CAS  PubMed  Google Scholar 

Baillie TA (2016) Targeted covalent inhibitors for Drug Design. Angew Chem Int Ed Engl 55(43):13408–13421

Article  CAS  PubMed  Google Scholar 

Bauer RA (2015) Covalent inhibitors in drug discovery: from accidental discoveries to avoided liabilities and designed therapies. Drug Discov Today 20(9):1061–1073

Article  CAS  PubMed  Google Scholar 

Barf T, Covey T, Izumi R, van de Kar B, Gulrajani M, van Lith B, van Hoek M, de Zwart E, Mittag D, Demont D, Verkaik S, Krantz F, Pearson PG, Ulrich R, Kaptein A (2017) Acalabrutinib (ACP-196): a covalent Bruton tyrosine kinase inhibitor with a differentiated selectivity and in vivo potency profiles. J Pharmacol Experimental Ther November 363(2):240–252

Article  CAS  Google Scholar 

Jaffe ES, Pittaluga S (2011) Aggressive B-cell lymphomas: a review of new and old entities in the WHO classification. Hematol Am Soc Hematol Educ Program 2011:506–514

Article  Google Scholar 

Alsagaby SA (2019) Transcriptomics-based validation of the relatedness of heterogeneous nuclear ribonucleoproteins to chronic lymphocytic leukemia as potential biomarkers of the disease aggressiveness. Saudi Med J 40(4):328–338

Article  PubMed  PubMed Central  Google Scholar 

Barr PM, Owen C, Robak T, Tedeschi A, Bairey O, Burger JA, Hillmen P, Coutre SE, Dearden C, Grosicki S, McCarthy H, Li JY, Offner F, Moreno C, Zhou C, Hsu E, Szoke A, Kipps TJ, Ghia P (2022) Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia. Blood Adv 6(11):3440–3450

Article  CAS  PubMed  PubMed Central  Google Scholar 

Woyach JA, Barr PM, Kipps TJ, Barrientos JC, Ahn IE, Ghia P, Girardi V, Hsu E, Jermain M, Burger JA (2023) Characteristics and clinical outcomes of patients with chronic lymphocytic Leukemia/Small lymphocytic lymphoma receiving Ibrutinib for ≥ 5